Research on prostate cancer biology, detection, and outcomes. Covers genetic clues, DNA damage, diet and survival, and screening awareness.
A new study found that men with prostate cancer who experience urinary, bowel, or sexual dysfunction after treatment are more likely to experience emotional distress, which can lead to worsening function. The researchers emphasize the need for greater investment in psychosocial care to mitigate treatment side effects and improve qualit...
Researchers found that activating olfactory receptor OR51E2 in prostate cancer cells causes aggressive castration-resistant disease, suggesting a new treatment approach. Blocking the receptor with specific molecules or scents could provide a new way to treat prostate cancer.
A novel long non-coding RNA, ARLNC1, controls signals from the androgen receptor, a key player in prostate cancer. Knocking down this RNA led to cancer cell death, suggesting it as a potential target for future therapies.
A study found that androgen deprivation therapy prolongs QTc interval duration, increasing risk of arrhythmia and sudden cardiac death in men with prostate cancer. Researchers urge oncologists to monitor QTc interval in patients receiving ADT.
A new study reveals declines in prostate cancer screening and diagnoses in the US between 2008-2014, with significant decreases in definitive treatments. The findings suggest that men are choosing active surveillance for low-risk prostate cancer, avoiding treatment-related harms.
A landmark study has delivered a final verdict on finasteride's impact on prostate cancer, finding it reduces risk without increasing mortality. Finasteride significantly lowers the risk of developing prostate cancer without causing an increased risk of dying from the disease.
A new blood test called IsoPSA has been shown to be more accurate in predicting overall risk of prostate cancer than standard PSA tests. The study found that nearly 40 percent of biopsies could have been avoided with the use of IsoPSA, potentially lowering overtreatment rates and reducing unnecessary procedures.
A new software tool called the automated bone scan index (aBSI) has been shown to be both accurate and speedy in calculating how extensively bones have been infiltrated by prostate cancer. The aBSI technology provided prognostic information about patient outcomes, including survival time and symptom progression.
A new study published in Urologic Oncology suggests that MRI fusion biopsy is a more effective method for detecting clinically significant prostate cancer in patients with prior negative biopsies. The study analyzed data from over 700 patients and found that fusion biopsy detected 30.7% of clinically significant cancers, compared to 4....
A study by NYU Langone Health and the VA found that increasing numbers of veterans with non-aggressive prostate cancer are opting for watchful waiting or active surveillance. This shift towards more conservative treatment reflects a reversal in decades-long overtreatment, bringing care more in line with best practice guidelines.
Researchers at University of Bath discovered a link between molecule 'oiliness' and potency against prostate cancer protein AMACR. The team designed test to measure activity levels and identified promising molecules that could lead to new anti-cancer drugs.
Researchers developed a method to identify men with locally advanced prostate cancer who are less likely to respond well to radiotherapy. A 28-gene signature accurately identifies hypoxic tumour tissue in patients with prostate cancer that invades nearby structures. This signature could lead to improved treatment outcomes for patients.
Research in Molecular Oncology reveals overexpression of interleukin-6 (IL6) in tumor-adjacent tissues among African-American men. This leads to inhibition of p53 tumor suppressor protein and promotes self-renewal of cancer cells.
The USPSTF recommends that men aged 55 to 69 consider discussing the benefits and harms of PSA-based screening with their doctor. Screening offers a small benefit of reducing prostate cancer death, but also potential harms like false positives and overdiagnosis.
Analysis of hundreds of human prostate tumors revealed that the most aggressive cancers depend on a built-in cellular stress response to put a brake on their own hot-wired physiology. Experiments showed that blocking this stress response causes treatment-resistant cancer cells to self-destruct while leaving normal cells unaffected.
A new web-based support programme offers online cognitive behavioural therapy and peer support to survivors of prostate cancer, aiming to improve their mental health. The programme has shown promising results in reducing distress and improving quality of life among men recovering from the disease.
Researchers developed a composite score to identify census tracts with high prostate cancer burden, considering incidence and mortality rates. The tool helps pinpoint clusters of high-risk areas that don't always align with demographics, highlighting the need for further study on underlying factors contributing to poor outcomes.
Researchers found a significant link between exposure to blue light at night and higher risks of developing breast and prostate cancer. The study used images taken by astronauts to evaluate outdoor lighting in Madrid and Barcelona.
Researchers found patients in the Prostate Cancer Intervention versus Observation Trial (PIVOT) to be up to eight times more likely to die than real-world patients. The study's patient population was also older and sicker, with an average age of 67 at diagnosis.
Researchers found that ultrahypofractionated radiotherapy is just as effective as standard radiotherapy in stopping prostate cancer from returning, with no significant long-term side effects. Patients treated with this method spend less time traveling to and from hospital for treatment.
Researchers analyzed 293 localized prostate cancer tumors and found that those with multiple types of cancer cells were the most aggressive. The study's findings can help determine the best approach for each individual patient, including sparing patients from unnecessary treatment.
Researchers at Duke University Medical Center have developed man-made aptamers that target prostate cancer cells, killing them while leaving healthy tissue unscathed. The findings suggest that these molecules could form the basis of new cancer therapies if further studies bear out.
A new study presents contrast-enhanced subharmonic imaging (SHI) as a promising tool for detecting prostate cancers not identified by MRI. SHI provides improved contrast signal and tissue suppression, leading to better visualization of microvascular architecture.
A new study from Ohio State University suggests that a comprehensive exercise and diet program in a group setting can help prostate cancer patients avoid weight gain and strength loss, reducing the risk of chronic health problems. The study found significant differences between men who participated in the program and those who did not.
Researchers have developed a new technology that can characterize gene expression at the level of individual cells in prostate cancer. The technique uses magnetic nanoparticles to trap and analyze circulating tumor cells, allowing for rapid and accurate detection of biomarkers associated with drug resistance.
A study published in the Journal of Clinical Oncology found that taking a standard prostate cancer drug with food can boost its impact and lower costs. By decreasing the daily dose, preventing digestive issues, and cutting costs by 75 percent, patients could save up to $300,000 per month.
A new approach to analyzing prostate gland tissue uses cellular metabolites to differentiate between aggressive and less aggressive tumors. The study found that metabolite levels can predict tumor grade, stage, and recurrence risk, helping guide treatment strategy.
Researchers discover microRNA molecule miR-940 that alters bone structure in late-stage prostate cancer. The molecule promotes osteoblastic lesions, which can cause severe pain and structural weakness.
A new analysis has found that the PIVOT study's patient population was not representative of real-world patients, with those in the trial being older and sicker. This raises significant questions about the validity of the study's findings and potential treatment recommendations.
A new machine learning model can accurately predict which patients are most likely to benefit from prostate multiparametric MRI (mpMRI), allowing for optimized patient selection and resource allocation. The model showed high accuracy in predicting PI-RADS category 4 or 5 lesions, with a sensitivity of 75% and specificity of 82%.
A study by Tampere University found new prostate cancer mechanisms that are not shown by genomic alterations, including changes in the citric acid cycle. Several potential new biomarkers of prostate cancer were also discovered.
A new study using Medicare claims data found that finasteride significantly reduces prostate cancer risk over a period of 16 years, with a 21% decrease in risk compared to those on a placebo. This long-term benefit is twice as long as previously recorded.
The study found that nearly half of the wives reported that their partner's health problem affected their own health, with many feeling increasingly socially isolated. The women also expressed concerns about the role change in their relationship as their husbands became less able to fulfill their usual roles.
A new study reveals that prostate MRI scans can reduce the number of invasive biopsies by up to 28% and detect more harmful cancers. The results show that using MRI to target biopsies leads to more significant cancer diagnoses, while also reducing unnecessary diagnoses.
A Chinese AI system can diagnose prostate cancer with accuracy comparable to human pathologists, offering potential benefits for streamlining cancer diagnosis and overcoming pathologist shortages. The system was developed using a learning algorithm and showed promise in accurately classifying malignancy levels and Gleason Grades.
A new study published in JAMA Oncology found that higher doses of radiation therapy did not improve survival rates for patients with intermediate-risk prostate cancer. However, the study did show lower rates of recurrence and tumor growth in the group receiving the higher dose, which could lead to better quality of life.
A new systematic review and meta-analysis of previous research found limited data to support the effectiveness of digital rectal exams for prostate cancer screening. The study concluded that existing studies were at risk of bias due to poor quality evidence.
A new genomic classifier score predicts aggressive prostate cancer, potentially changing treatment guidelines. The model integrates gene expression biomarker risk scores into existing risk groups, increasing accuracy and confidence in treatment recommendations.
A recent trial found that a one-off PSA test does not save lives in asymptomatic men, highlighting the need for more accurate ways to diagnose aggressive prostate cancers. The study of over 400,000 men aged 50-69 showed no significant difference in mortality rates between those who were screened and those who were not.
A single PSA test increased detection of low-risk prostate cancer, but made no significant difference in prostate cancer deaths after 10 years. This study suggests that current policy against prostate cancer screening may be justified, as potential benefits are outweighed by harms from overdetection and overtreatment.
A novel nuclear medicine imaging agent targeting copper accumulation in tumors detects prostate cancer recurrence early in patients with biochemical relapse. The new imaging agent, copper-64 chloride (64CuCl2), has a higher detection rate than fluorine-18-choline-PET/CT in patients with low levels of PSA (<1 ng/ml).
A recent study found that nearly half of all prostate cancer randomized clinical trials use lab results that disproportionately exclude black patients. The study, published in JAMA Oncology, highlights the need for researchers to adjust entry criteria to prevent racial biases.
A phase 3 clinical trial showed apalutamide treatment significantly delayed metastasis development in men with prostate cancer resistant to standard therapy. The treatment also improved survival and reduced disease progression symptoms.
A recent study revealed that patients with inherited DNA repair mutations in metastatic prostate cancer can derive similar benefits from treatment with standard therapies as other patients. Ongoing research explores the potential potency of targeted therapy with PARP inhibitors, which may offer additional therapeutic options for these ...
Researchers have developed a new method to differentiate cancerous tissue from healthy tissue in prostate cancer patients using PSMA PET/CT scans. The study found that a cutoff value of SUV max = 3.15 can accurately diagnose prostate cancer with high sensitivity and specificity.
PSMA PET/CT detects prostate cancer recurrence earlier than current imaging modalities, enabling more effective salvage radiotherapy. Nearly half of patients with biochemical recurrence show positive results, with lesions often found in bone and perirectal lymph nodes.
A large retrospective study found that obese men and those with metabolic syndrome had a higher risk of biochemical recurrence after radical prostatectomy. Patients with obesity had a 32% higher chance of recurrence compared to those with normal weight, while those with metabolic syndrome had over four-fold increased risk.
Researchers confirmed a mechanistic link between HSD17B4 and treatment-resistant prostate cancer. The study found that men lacking a specific isoform of the gene are more susceptible to aggressive prostate cancer.
A new genetic tool predicts the age of onset for aggressive prostate cancer, guiding decisions on PSA screening. The polygenic hazard score is a highly significant predictor of age at diagnosis, estimating individual genetic risk.
A new genetic risk model predicts age of onset for aggressive prostate cancer, guiding screening decisions. Men with high scores are at almost three-fold greater risk of developing aggressive disease.
A new study found that a Mediterranean diet rich in fish, boiled potatoes, fruits, vegetables, legumes, and olive oil was associated with a lower risk of aggressive prostate cancer. The diet showed a protective effect on more aggressive tumors, but other dietary patterns had little to no correlation.
Researchers at Hokkaido University have identified a cellular protein called STAP-2 that stabilizes the EGFR signaling pathway, leading to increased cell proliferation and tumor formation in prostate cancer. Suppressing STAP-2 with inhibitors could potentially treat Gefitinib-resistant prostate cancers.
A study published in Oncotarget identifies a key step in the modification of Snail1, which can alter its structure and function to promote prostate cancer cell migration. The researchers found that preventing this modification can abolish the migratory and invasive properties of human prostate cancer cells.
A five-year, nearly $12 million study will compare the effectiveness of two radiation treatments for prostate cancer, proton therapy and intensity-modulated radiation therapy (IMRT). The study aims to determine if proton therapy has fewer side effects compared to IMRT.
An international panel of experts has developed a comprehensive set of recommendations for genetic counseling and testing in men with high-risk prostate cancer. The guidelines aim to inform screening, treatment planning, and personalized care, taking into account the rapidly evolving field of practice.
A new study found that a shorter course of radiation therapy using higher doses over fewer days may provide a better outcome for men with intermediate-risk prostate cancer. The study analyzed data from over 5,000 men and showed a significant 13% reduction in the risk of recurrence with hypofractionated radiation therapy (HRT) compared ...
A study by Australian researchers demonstrates that PSMA PET scans can identify prostate cancer patients who would benefit from salvage radiation treatment. The study shows an overall treatment response of 72 percent, with men having negative or fossa-confined PSMA having the highest treatment response to SRT.
A new method using single-cell genomics can help identify potentially lethal prostate tumors before surgery, improving risk assessment and treatment decisions. The approach analyzes genomic patterns in biopsy cores, assigning a score based on clonality and genetic aberrations.
A new study at the University of Michigan identifies a pathway that links efferocytosis, the process of removing dead cells, to tumor growth in metastatic prostate cancer. The researchers found that a pro-inflammatory protein called CXCL5 accelerates tumor growth and sheds light on novel effective cancer therapies.
The Prostate Health Index test influences physician decisions to perform biopsies, with only 36% of men receiving biopsies when phi testing was included in the assessment compared to 60% before its availability. The study also found a reduction in low-grade prostate cancers detected.